Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IC19/1563 in Relapsed/Refractory B Cell Malignancies
NCT04892277Phase 1Recruiting
- Sponsor
- Mayo Clinic
- Start
- Oct 2022
- Primary completion
- Mar 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IC19/1563 in B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by Mayo Clinic. Primary endpoint: Maximum Tolerated Dose at 90 days. Started Oct 2022; status: recruiting.
02
Drugs
IC19/1563
03
Conditions
B-cell non-Hodgkin lymphomachronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04892277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04892277.